A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Фаза 2
Идёт, набор закрыт
NCT04640623
| Заболевание | Urinary Bladder Neoplasms |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 220 участн. |
|---|
| Вмешательство | TAR-200, Cetrelimab |
|---|
| Дата начала | 18.12.2020 |
|---|
| Дата завершения | 3.07.2025 |
|---|
| Публикация результатов | 29.07.2026 |
|---|
Кратко
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).
Cohorts 1, 2, and 3: Overall Complete Response (CR) Rate
From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months) · percentage of participants
| Cohort 1: TAR-200 + Cetrelimab (CIS With or Without Papillary Disease) | 67.9 percentage of participants |
|---|
| Cohort 2: TAR-200 Monotherapy (CIS With or Without Papillary Disease) | 82.4 percentage of participants |
|---|
| Cohort 3: Cetrelimab IV Monotherapy (CIS With or Without Papillary Disease) | 46.4 percentage of participants |
|---|
Cohort 4: Disease-free Survival (DFS)
From date of first dose up to clinical cut-off date 3rd July 2025 (up to 50 months) · months
| Cohort 4: TAR-200 Monotherapy (Papillary Disease Only) | NA months |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.